ArticleNeurocritical care2026
A Biomarker Coming of AGE: Skin Autofluorescence Predicts Functional Outcome after Aneurysmal Subarachnoid Hemorrhage.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly risk stratification following aneurysmal subarachnoid hemorrhage (aSAH) is clinically challenging. Beyond the initial hemorrhage severity, chronic metabolic vulnerability may contribute to secondary brain injury. Skin autofluorescence (SAF) is a rapid, noninvasive bedside biomarker that quantifies advanced glycation end product (AGE) accumulation. The prognostic relevance after aSAH has not been characterized previously.
methodsIn a prospective single-center cohort study, SAF was measured during the index hospital stay in consecutive adult patients with confirmed aSAH. The primary endpoint was poor functional outcome at 90 days, defined as a modified Rankin Scale (mRS) score of 4-6. Secondary endpoints included delayed cerebral ischemia (DCI; defined as delayed neurological deterioration ≥ 1 h and/or new cerebral infarction not attributable to other causes) and radiographic vasospasm. Associations were assessed using logistic regression and receiver operating characteristic (ROC) curve analyses.
resultsA total of 50 patients completed 90-day follow-up; 22 (44%) experienced poor functional outcome. SAF demonstrated a strong association with poor functional outcome (logistic regression coefficient 2.28, p = 0.001), yielding an approximate odds ratio of 9.8 per unit increase. Discriminative performance was excellent (AUC 0.81). An optimal SAF cutoff value of ≥ 2.6 yielded a sensitivity of 0.82, specificity of 0.71, positive predictive value of 0.69, and negative predictive value of 0.83. SAF showed a moderate association with DCI (p = 0.045; AUC 0.68) but not with radiographic vasospasm (p = 0.35). SAF remained robustly associated with poor functional outcome after controlling for age, baseline disease severity, DCI and vasospasm.
conclusionsBedside SAF predicts poor 90-day functional outcome following aSAH and is associated with DCI, but not with radiographic vasospasm. These findings support a pathophysiological role for chronic metabolic vulnerability in determining secondary brain injury severity and functional recovery after aSAH. The prospective cohort is currently being expanded, and external validation in larger prospective multicenter cohorts is warranted.
Indexed as
Identifiers
42587217What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.